Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

4/9/2025

Janusmed kön och genus

Janusmed kön och genus – Mifegyne

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
B B
B B

Mifepriston Testmiljö

Mifepriston

Klass : B

Visa all info

Skriv ut

Kontakta oss

Produkter

Mifecur, Mifegyne, Mifepristone Linepharma

Mifecur, Mifegyne, Mifepristone Linepharma
ATC-koder

G03XB01

G03XB01
Substanser

mifepriston

mifepriston
Sammanfattning

Mifepriston är godkänt på indikation avbrytande av pågående intrauterin graviditet. Substansen används i detta syfte endast av kvinnor varför analys avseende könsskillnader inte bedömts relevant. Mifepriston används även utanför denna indikation men könsanalyser saknas.

Mifepriston är godkänt på indikation avbrytande av pågående intrauterin graviditet. Substansen används i detta syfte endast av kvinnor varför analys avseende könsskillnader inte bedömts relevant. Mifepriston används även utanför denna indikation men könsanalyser saknas.
Background

Mifepristone is a synthetic steroid blocking progesterone [1]. It is approved on the indications induction of abortion during first trimester (in combination with prostaglandins), post coital contraception and cervical ripening prior to suction termination of pregnancy [1-3]. For these indications the substance is only used in women and analyses on sex or gender differences have therefore not been considered relevant.

Mifepristone has also been studied in Cushing’s Disease in patients with ectopic ACTH-secreting neoplasms or adrenocortical carcinoma to control hypercortisolism while waiting for definitive therapy [4-6]. Both men and women have been included in the studies but no analysis of sex differences has been found even though Spitz et al report sex divided data [6]. Clinical studies of the effect of mifepristone on neuroleptic induced weight gain have been performed in men, thus sex-divided analysis in this therapeutic area is also lacking [7, 8].

Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of mifepris......

Visa hela bakgrundstexten

Mifepristone is a synthetic steroid blocking progesterone [1]. It is approved on the indications induction of abortion during first trimester (in combination with prostaglandins), post coital contraception and cervical ripening prior to suction termination of pregnancy [1-3]. For these indications the substance is only used in women and analyses on sex or gender differences have therefore not been considered relevant. Mifepristone has also been studied in Cushing’s Disease in patients with ectopic ACTH-secreting neoplasms or adrenocortical carcinoma to control hypercortisolism while waiting for definitive therapy [4-6]. Both men and women have been included in the studies but no analysis of sex differences has been found even though Spitz et al report sex divided data [6]. Clinical studies of the effect of mifepristone on neuroleptic induced weight gain have been performed in men, thus sex-divided analysis in this therapeutic area is also lacking [7, 8]. # Pharmacokinetics and dosing No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of mifepristone have been found. # Effects No studies with a clinically relevant sex analysis regarding effects of mifepristone have been found. # Adverse effects Controlled studies on adverse effects between men and women in mifepristone safety are lacking although there is one study presenting sex-divided data on adverse events in treatment of Cushing Disease [6]. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Läkemedel innehållande mifepriston (ATC-kod G03XB01) används huvudsakligen på sjukhus och därför saknas könsspecifika användningsdata [9].
Referenser

Visa referenser

  1. Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999

  2. Mifegyne (mifepriston). Fass.se [www]. [updated 2015-12-10, cited 2017-04-11].

  3. Physicians' Desk Reference. http://www.pdr.net. [cited 2017-04-11].

  4. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317:516-524.

  5. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-49.

  6. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril. 2005;84:1719-26.

  7. Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther. 2009;26:959-69.

  8. Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring). 2010;18:2295-300.

  9. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]

  1. Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999
  2. Mifegyne (mifepriston). Fass.se [www]. [updated 2015-12-10, cited 2017-04-11].
  3. Physicians' Desk Reference. http://www.pdr.net. [cited 2017-04-11].
  4. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317:516-524.
  5. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-49.
  6. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril. 2005;84:1719-26.
  7. Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther. 2009;26:959-69.
  8. Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring). 2010;18:2295-300.
  9. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]
Uppdaterat

Litteratursökningsdatum: 4/11/2017

Litteratursökningsdatum: 4/11/2017
B B
B B

Mifepriston Testmiljö

Mifepriston

Klass : B

Visa all info

Skriv ut

Kontakta oss

Produkter

Mifecur, Mifegyne, Mifepristone Linepharma

Mifecur, Mifegyne, Mifepristone Linepharma
ATC-koder

G03XB01

G03XB01
Substanser

mifepriston

mifepriston
Sammanfattning

Mifepriston är godkänt på indikation avbrytande av pågående intrauterin graviditet. Substansen används i detta syfte endast av kvinnor varför analys avseende könsskillnader inte bedömts relevant. Mifepriston används även utanför denna indikation men könsanalyser saknas.

Mifepriston är godkänt på indikation avbrytande av pågående intrauterin graviditet. Substansen används i detta syfte endast av kvinnor varför analys avseende könsskillnader inte bedömts relevant. Mifepriston används även utanför denna indikation men könsanalyser saknas.
Background

Mifepristone is a synthetic steroid blocking progesterone [1]. It is approved on the indications induction of abortion during first trimester (in combination with prostaglandins), post coital contraception and cervical ripening prior to suction termination of pregnancy [1-3]. For these indications the substance is only used in women and analyses on sex or gender differences have therefore not been considered relevant.

Mifepristone has also been studied in Cushing’s Disease in patients with ectopic ACTH-secreting neoplasms or adrenocortical carcinoma to control hypercortisolism while waiting for definitive therapy [4-6]. Both men and women have been included in the studies but no analysis of sex differences has been found even though Spitz et al report sex divided data [6]. Clinical studies of the effect of mifepristone on neuroleptic induced weight gain have been performed in men, thus sex-divided analysis in this therapeutic area is also lacking [7, 8].

Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of mifepris......

Visa hela bakgrundstexten

Mifepristone is a synthetic steroid blocking progesterone [1]. It is approved on the indications induction of abortion during first trimester (in combination with prostaglandins), post coital contraception and cervical ripening prior to suction termination of pregnancy [1-3]. For these indications the substance is only used in women and analyses on sex or gender differences have therefore not been considered relevant. Mifepristone has also been studied in Cushing’s Disease in patients with ectopic ACTH-secreting neoplasms or adrenocortical carcinoma to control hypercortisolism while waiting for definitive therapy [4-6]. Both men and women have been included in the studies but no analysis of sex differences has been found even though Spitz et al report sex divided data [6]. Clinical studies of the effect of mifepristone on neuroleptic induced weight gain have been performed in men, thus sex-divided analysis in this therapeutic area is also lacking [7, 8]. # Pharmacokinetics and dosing No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of mifepristone have been found. # Effects No studies with a clinically relevant sex analysis regarding effects of mifepristone have been found. # Adverse effects Controlled studies on adverse effects between men and women in mifepristone safety are lacking although there is one study presenting sex-divided data on adverse events in treatment of Cushing Disease [6]. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Läkemedel innehållande mifepriston (ATC-kod G03XB01) används huvudsakligen på sjukhus och därför saknas könsspecifika användningsdata [9].
Referenser

Visa referenser

  1. Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999

  2. Mifegyne (mifepriston). Fass.se [www]. [updated 2015-12-10, cited 2017-04-11].

  3. Physicians' Desk Reference. http://www.pdr.net. [cited 2017-04-11].

  4. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317:516-524.

  5. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-49.

  6. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril. 2005;84:1719-26.

  7. Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther. 2009;26:959-69.

  8. Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring). 2010;18:2295-300.

  9. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]

  1. Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999
  2. Mifegyne (mifepriston). Fass.se [www]. [updated 2015-12-10, cited 2017-04-11].
  3. Physicians' Desk Reference. http://www.pdr.net. [cited 2017-04-11].
  4. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317:516-524.
  5. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-49.
  6. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril. 2005;84:1719-26.
  7. Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther. 2009;26:959-69.
  8. Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring). 2010;18:2295-300.
  9. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]
Uppdaterat

Litteratursökningsdatum: 4/11/2017

Litteratursökningsdatum: 4/11/2017